Ideaya Biosciences Inc

NASDAQ:IDYA   3:59:51 PM EDT
24.48
+0.99 (+4.22%)
Products, Regulatory

IDEAYA Reports IDE397 Phase 1 Clinical Pharmacodynamic Data

Published: 06/28/2021 12:26 GMT
Ideaya Biosciences Inc (IDYA) - Ideaya Announces Ide397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination.
Ideaya Biosciences Inc - Observation of a Clinical Pharmacodynamic Signal in Initial Cohorts of Ide397 Dose Escalation Study is Significant.
Ideaya Biosciences Inc - Ide397 Has Initiated Third Cohort of Dose Escalation Portion of Phase 1 Clinical Trial.
Ideaya Biosciences - Earlier Reported Unconfirmed Partial Responses Confirmed in a Patient in Each of the Combination.